QCG
BCAX

Quadrant Capital Group’s Bicara Therapeutics BCAX Stock Holding History

Quadrant Capital Group’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13
Closed -$259 – 2682
2026
Q1 		$259 Buy
+13
New +$224 ﹤0.01% 2654

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Quadrant Capital Group's BCAX Position: Q2 2026 in Review

Quadrant Capital Group sold out of Bicara Therapeutics (BCAX) in Q2 2026, closing a stake of 13 shares — an estimated $259 sold.

Quadrant Capital Group first reported a position in BCAX in Q1 2026 and held it in 1 quarter. The position peaked at $259 in Q1 2026. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Quadrant Capital Group reported no remaining Bicara Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 13 Bicara Therapeutics shares in Q2 2026, an estimated $259.
  • Quadrant Capital Group first reported a position in Bicara Therapeutics in Q1 2026 and held it in 1 quarter.
  • Quadrant Capital Group's Bicara Therapeutics position peaked at $259 in Q1 2026.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.